Recurrent urinary tract infections in adults: a practical guide

2021 ◽  
pp. 1-11
Author(s):  
Thomas Hughes ◽  
Patrick Juliebø-Jones ◽  
Louis Saada ◽  
Kordo Saeed ◽  
Bhaskar K Somani
Keyword(s):  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Treatment Strategies ◽  
Holistic Management ◽  
Recurrent Urinary Tract Infections ◽  
Management Approaches ◽  
Tract Infections ◽  
Prevention Methods ◽  
Rule Out

Recurrent urinary tract infections are a common problem faced by clinicians across many specialities. For the patient, recurrent urinary tract infections can be burdensome and detrimental to their quality of life. For the clinician, they can be challenging to manage, and the socioeconomic burden on healthcare systems can also be substantial. Investigations serve to rule out any underlying structural or pathological abnormalities. In conjunction with behavioural prevention methods, treatment strategies include antibiotic and non-antibiotic approaches and holistic management approaches. This article provides an overview of the investigation and treatment of urinary tract infections and includes algorithms which can be used in daily clinical practice.

PD58-12 DISCREPANCIES IN PATIENT AND PHYSICIAN PERSPECTIVES OF QUALITY OF CARE DELIVERED TO PATIENTS WITH RECURRENT URINARY TRACT INFECTIONS

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Taylor Y. Sadun* ◽  
Victoria C.S. Scott ◽  
Lauren W. Thum ◽  
Melissa Markowitz ◽  
Sally L. Maliski ◽  
...  
Keyword(s):  
Quality Of Care ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Recurrent Urinary Tract Infections ◽  
Physician Perspectives ◽  
Tract Infections

scholarly journals Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections: Results from a multicentre survey

2014 ◽  
Vol 8 (9-10) ◽  
pp. 721 ◽  
Author(s):  
Antonio Cicione ◽  
Francesco Cantiello ◽  
Giuseppe Ucciero ◽  
Andrea Salonia ◽  
Marco Torella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hyaluronic Acid ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Chondroitin Sulphate ◽  
Recurrent Utis ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections

Introduction: We assess the effectiveness of intravesical instillation of hyaluronic acid (HA) and chondroitin sulphate (CS) as a non-antibiotic treatment option for prophylaxis of recurrent urinary tract infections (UTIs) in female patients.Methods: This was a retrospective cohort study involving 7 European institutions. We included patients with recurrent UTIs who received intravesical instillations of Ialuril (IBSA International) (50 mL HA 1.6% and CS 2% solution) between January 2010 and March 2012. Medication schedule, length of follow-up, recurrence infection time, number of UTIs/patients/year, patient quality of life, subjective symptoms score, and treatment-emergent side effects were recorded and analyzed.Results: In total, 157 women (mean age: 54.2 ± 4.1 years) were included in the analysis. All patients had at least 12 months follow-up. After 4 weekly and 5 monthly HA-CS bladder instillations, UTI episodes decreased from 4.13 ± 1.14 to 0.44 ± 0.50 (p = 0.01) at 12 months, while recurrent UTI time prolonged from 94.8 ± 25.1 days to 178.4 ± 37.3 days (p = 0.01) at 12 months. An improvement in symptoms and quality of life was achieved. A medium-depth pain after medication instillation was the most reported side effect. Regression model analysis showed significant risk factors in developing new UTI episodes: being more than 50 years old and having more than 4 UTI episodes per year (OR 3.41; CI 95%; 1.51-7.71, p = 0.003 and OR 3.31; CI 95% 1.51-7.22; p = 0.003, respectively). Retrospective design and lack of a control group represent two main limitations of the study.Conclusions: Restoring glycosaminoglycans bladder layer therapy is a promising non-antibiotic therapy to prevent recurrent UTIs.

scholarly journals D-MannosE to prevent Recurrent urinary tract InfecTions (MERIT): protocol for a randomised controlled trial

BMJ Open ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. e037128
Author(s):  
Marloes Franssen ◽  
Johanna Cook ◽  
Jared Robinson ◽  
Nicola Williams ◽  
Margaret Glogowska ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Negative Impact ◽  
Controlled Trial ◽  
Pragmatic Trial ◽  
Double Blind ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections

IntroductionRecurrent urinary tract infections (RUTIs) have a significant negative impact on quality of life and healthcare costs. To date, daily prophylactic antibiotics are the only treatment which have been shown to help prevent RUTIs. D-mannose is a type of sugar which is believed to inhibit bacterial adherence to uroepithelial cells, and is already being used by some women in an attempt to prevent RUTIs. There is currently insufficient rigorous evidence on which to base decisions about its use. The D-mannose to prevent recurrent urinary tract infections (MERIT) study will evaluate whether D-mannose is clinically and cost-effective in reducing frequency of infection and symptom burden for women presenting to UK primary care with RUTI.Methods and analysisMERIT will be a two-arm, individually randomised, double blind placebo controlled, pragmatic trial. Participants will be randomised to take D-mannose powder or placebo powder daily for 6 months. The primary outcome will be the number of medical attendances attributable to symptoms of RUTI. With 508 participants we will have 90% power to detect a 50% reduction in the chance of a further clinically suspected UTI, assuming 20% lost to follow-up. Secondary outcomes will include: number of days of moderately bad symptoms of UTI; time to next consultation; number of clinically suspected UTIs; number of microbiologically proven UTIs; number of antibiotic courses for UTI; quality of life and healthcare utilisation related to UTI. A within trial economic evaluation will be conducted to examine cost-effectiveness of D-mannose in comparison with placebo. A nested qualitative study will explore participants’ experiences and perceptions of recruitment to, and participation in a study requiring a daily treatment.Ethics and disseminationEthical approval has been obtained from South West-Central Bristol Research Ethics Committee. Publication of the MERIT study is anticipated to occur in 2021.Trial registration numberISRCTN 13283516.

Premenopausal women with recurrent urinary tract infections have lower quality of life

2018 ◽  
Vol 25 (7) ◽  
pp. 684-689 ◽  
Author(s):  
Siobhan S Ennis ◽  
Huifang Guo ◽  
Lata Raman ◽  
Paul A Tambyah ◽  
Swaine L Chen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Urinary Tract ◽  
Urinary Tract Infections ◽  
Premenopausal Women ◽  
Recurrent Urinary Tract Infections ◽  
Tract Infections
Sign in / Sign up

Export Citation Format

Share Document